Skip to main content
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. — Investor Relations & Filings

Ticker · ORKA ISIN · US6876041087 US Manufacturing
Open in API
Filings indexed 996 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country US United States of America
Listing US ORKA

About Oruka Therapeutics, Inc.

https://orukatx.com/

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel biologics for chronic skin diseases and other inflammatory conditions. The company applies advanced antibody engineering to validated modes of action to create potentially best-in-class monoclonal antibodies. Its lead program, ORKA-001, targets the IL-23 cytokine for the treatment of moderate-to-severe plaque psoriasis. Oruka's mission is to redefine the standard of care by developing treatments that achieve high rates of complete disease clearance with a significantly reduced dosing frequency, potentially requiring only one or two doses per year.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 97% confidence The document is a U.S. SEC Form 8-K Current Report filed under Section 13 or 15(d) of the Exchange Act. It announces a contract amendment (IL-23 License Agreement) and attaches it as an exhibit. There are no financial statements or earnings data, and it is an unscheduled report of a significant event, so it is a general regulatory filing rather than an annual, interim, earnings, or other specialized report.
2026-06-01 English
10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text includes details about a recent financing event: an underwriting agreement and the sale of common stock shares. It also provides preliminary financial information related to cash and investments as of a recent date, but it does not contain full financial statements or comprehensive financial analysis. The document is primarily focused on the capital raising transaction and related disclosures. Therefore, it fits best into the category of Capital/Financing Update (CAP). The document length (9228 characters) and content confirm it is not a brief announcement or a full annual/interim report, but a detailed current report on financing activity.
2026-04-30 English
424B5 - Oruka Therapeutics, Inc. (0000907654) (Filer)
Capital/Financing Update Classification · 95% confidence The document is titled 'Preliminary Prospectus Supplement' and references a registration statement filed under the Securities Act of 1933. It discusses an offering of common stock, underwriting discounts, use of proceeds, risk factors, and other details typical of a securities offering document. The presence of terms like 'prospectus supplement,' 'registration statement,' 'offering price,' and 'underwriters' clearly indicates this is a capital raising document. It is not a financial report, earnings release, or management discussion. It is a filing related to a securities offering, specifically a prospectus supplement under Rule 424(b)(5), which is a type of capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2026-04-27 English
424B5 - Oruka Therapeutics, Inc. (0000907654) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Preliminary Prospectus Supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It relates to an offering of common stock and pre-funded warrants, including details about the offering size, underwriting, risk factors, and use of proceeds. The document is a registration and offering prospectus supplement, which is a capital raising document. It is not a financial report, earnings release, management discussion, or any other type of report. It is clearly a capital/financing update related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not an RPA or RNS filing.
2026-04-27 English
8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 27, 2026, by Oruka Therapeutics, Inc. It reports on the results of a Phase 2a clinical trial (EVERLAST-A) for their drug ORKA-001. The filing includes a press release and a presentation as exhibits, and announces a conference call to discuss the data. The content focuses on clinical trial results and related announcements rather than detailed financial statements or comprehensive annual or quarterly financial reports. The document is not an earnings release (ER) since it does not primarily announce quarterly financial results, nor is it an annual or interim report. It is also not a management report or investor presentation by itself, but a regulatory filing to disclose material events. The Form 8-K is a current report used to announce significant events. Therefore, the filing type is Regulatory Filings (RNS), which is the appropriate category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2026-04-27 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.